6-甲氧基-1,2,3,4-四氢异喹啉-7-醇 | 1011-42-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 四氢异喹啉
• 中文名称: 6-甲氧基-1,2,3,4-四氢异喹啉-7-醇
• 英文名称: 7-Hydroxy-6-methoxy-1,2,3,4-tetrahydro-isochinolin
• 英文别名: 7-hydroxy-6-methoxy-1,2,3,4-tetrahydroisoquinoline；1,2,3,4,-Tetrahydro-7-hydroxy-6-methoxyisochinolin；6-Methoxy-1,2,3,4-tetrahydroisoquinolin-7-ol
• CAS: 1011-42-3
• 化学式: C₁₀H₁₃NO₂
• mdl: MFCD01846401
• 分子量: 179.219
• InChiKey: QWWUCLLPHZUUDS-UHFFFAOYSA-N

物化性质

• 熔点：
  283-285℃ (methanol )
• 密度：
  1.158±0.06 g/cm3 (20 ºC 760 Torr)

计算性质

• 辛醇/水分配系数(LogP)：
  0.9
• 重原子数：
  13
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.4
• 拓扑面积：
  41.5
• 氢给体数：
  2
• 氢受体数：
  3

安全信息

• 海关编码：
  2933499090

反应信息

• 作为反应物：
  描述：

  6-甲氧基-1,2,3,4-四氢异喹啉-7-醇 在 sodium hydroxide 、 sodium hydride 、 N,N-二异丙基乙胺 、 sodium iodide 作用下， 以 乙腈 、 丁酮 为溶剂， 反应 66.0h， 生成 α-(3,4-dimethoxyphenyl)-3,4-dihydro-7-[2-(1H-imidazol-1-yl)ethoxy]-6-methoxy-α-[(4-methylphenyl)thio]-2(1H)-isoquinolineheptanenitrile
  参考文献：
  名称：

  新型多药耐药逆转剂。

  摘要：

  合成了一系列59个α-芳基-α-硫醚-烷基，-链烯腈和-链烷羧酸甲酯四氢异喹啉和异吲哚啉衍生物（15a-48），并作为多药耐药性（MDR）逆转剂进行了评估。该化合物在针对比桑坦烯具有抗药性的S1-B1-20人结肠癌细胞上进行了测试。既确定了逆转剂的细胞毒性，又确定了它们使细胞对bisantrene敏感的能力。除了两种化合物（15q，40）以外，所有这些化合物在体外均比维拉帕米（VRP）（一种钙通道拮抗剂，也已显示具有MDR调节活性）更有效地逆转MDR。有几项在此分析中显示出良好的活性（IC50 <0.5 microM），最有效的是异吲哚啉44（IC50 0.26 microM）和46（IC50 0）。26 microM）和四氢异喹啉47（IC50 0.29 microM）和15m（IC50 0.30 microM）。在体内评估了许多化合物对无长春新碱（VCR）耐药的小鼠P388白血病以及无胸腺小鼠中植入人表皮样癌KB

  DOI：

  10.1021/jm9804477
• 作为产物：
  描述：

  聚合甲醛 、 4-苄氧基-3-甲氧基苯乙胺 在 乙醇 、 水 作用下， 生成 6-甲氧基-1,2,3,4-四氢异喹啉-7-醇
  参考文献：
  名称：

  Onda et al., Yakugaku Zasshi/Journal of the Pharmaceutical Society of Japan, 1956, vol. 76, p. 409,410, 411

  摘要：

  DOI：

文献信息

• ACETAMIDO-PHENYLTETRAZOLE DERIVATIVES AND METHODS OF USING THE SAME
  申请人：Athenex, Inc.

  公开号：US20220106312A1

  公开（公告）日：2022-04-07

  The present disclosure relates to compounds of Formula (IA) and to their prodrugs, pharmaceutically acceptable salts, pharmaceutical compositions, methods of use, and methods for their preparation. The compounds disclosed herein are useful for the treatment of disorders in which P-glycoprotein and/or cytochrome P450 (e.g. CYP3A4) is modulated (e.g., cancers which have developed multi-drug resistance).

  本公开涉及式（IA）化合物及其前药、药学上可接受的盐、药物组合物、使用方法以及制备方法。本文披露的化合物可用于治疗P-糖蛋白和/或细胞色素P450（例如CYP3A4）被调节的疾病（例如已发展多药耐药性的癌症）。
• Syntheses of tetrahydroisoquinoline derivatives that inhibit NO production in activated BV-2 microglial cells
  作者：Jai Woong Seo、Ekaruth Srisook、Hyo Jin Son、Onyou Hwang、Young-Nam Cha、Dae Yoon Chi

  DOI：10.1016/j.ejmech.2007.09.009

  日期：2008.6

  Seventeen tetrahydroisoquinoline derivatives were designed, synthesized and evaluated for inhibition of NO production in lipopolysaccharide-stimulated BV-2 microglial cells. Compounds 5a, 9c and 11a potently attenuated NO production by >60%, and 5a and 11a inhibited BH4 production by >48% at 100 microM. In particular, N-ethylcarbonyl-7-hydroxy-6-methoxy-1,2,3,4-tetrahydroisoquinoline (11a) reduced

  设计，合成和评估了十七种四氢异喹啉衍生物对脂多糖刺激的BV-2小胶质细胞中NO生成的抑制作用。化合物5a，9c和11a在100 microM时可有效地将NO生成减弱> 60％，而5a和11a将BH4生成抑制> 48％。特别地，N-乙基羰基-7-羟基-6-甲氧基-1，2，3，4-四氢异喹啉（11a）使NO产生减少64％，而四氢生物蝶呤（ ）产生减少49％。在C1或N2位置引入更长的烷基组分导致抑制作用的减弱。11a可能通过阻断新合成的iNOS单体的 依赖性二聚作用来抑制NO的产生。
• 1,2,3,4-TETRAHYDROISOQUINOLINE DERIVATIVES HAVING EFFECTS OF PREVENTING AND TREATING DEGENERATIVE AND INFLAMMATORY DISEASES
  申请人：Hwang On-You

  公开号：US20100217003A1

  公开（公告）日：2010-08-26

  Provided are 7-hydroxy-6-methoxy-1,2,3,4-tetrahydroisoquinoline derivatives and synthesis methods thereof. The compounds significantly inhibit the production of nitrogen monoxide (NO) and superoxide in an activated microglial cell and expressions of TNF-α, IL-1β inducive NO synthase and cyclooxygenase-2 genes. They also prevent NF-kB shift to a nucleus, decrease reactive oxygen species (ROS), inhibit expression of GTP cyclohydrolase I gene and over-production of tetrahydrobiopterin (BH 4 ), and protect dopaminergic neurons from injury due to activated microglial cells. Consequently, the compounds are effective in treating inflammatory and neurodegenerative diseases.

  提供了7-羟基-6-甲氧基-1,2,3,4-四氢异喹啉衍生物及其合成方法。这些化合物显著抑制活化小胶质细胞中一氧化氮（NO）和超氧化物的产生，以及TNF-α、IL-1β诱导NO合成酶和环氧合酶-2基因的表达。它们还可以防止NF-kB转移到细胞核，降低活性氧自由基（ROS）的水平，抑制GTP环水合酶I基因的表达和四氢生物蝶呤（BH4）的过度产生，并保护多巴胺能神经元免受活化小胶质细胞引起的损伤。因此，这些化合物对于治疗炎症和神经退行性疾病具有有效性。
• Urea derivatives
  申请人：Yura Takeshi

  公开号：US20050154230A1

  公开（公告）日：2005-07-14

  This invention relates to urea derivatives and salts thereof which is useful as an active ingredient of pharmaceutical preparations. The urea derivatives of the present invention has an excellent activity as VR1 antagonist and useful for the prophylaxis and treatment of diseases associated with VR1 activity, in particular for the treatment of urge urinary incontinence, overactive bladder, chronic pain, neuropathic pain, postoperative pain, rheumatoid arthritic pain, neuralgia, neuropathies, algesia, nerve injury, ischaemia, neurodegeneration, stroke, incontinence and/or inflammatory disorders.

  这项发明涉及脲衍生物及其盐，可用作制药制剂的活性成分。本发明的脲衍生物具有出色的VR1拮抗剂活性，可用于预防和治疗与VR1活性相关的疾病，特别是用于治疗急迫性尿失禁、过度活动膀胱、慢性疼痛、神经痛、术后疼痛、类风湿关节痛、神经痛、神经病、疼痛、神经损伤、缺血、神经退行性疾病、中风、失禁和/或炎症性疾病的治疗。
• The Discovery of Capsazepine, the First Competitive Antagonist of the Sensory Neuron Excitants Capsaicin and Resiniferatoxin
  作者：Christopher S. J. Walpole、Stuart Bevan、Guenter Bovermann、Johann J. Boelsterli、Robin Breckenridge、John W. Davies、Glyn A. Hughes、Iain James、Lukas Oberer、Janet Winter、Roger Wrigglesworth

  DOI：10.1021/jm00039a006

  日期：1994.6.1

  Capsaicin and resiniferatoxin are natural products which act specifically on a subset of primary afferent sensory neurons to open a novel cation-selective ion channel in the plasma membrane. These sensory neurons are involved in nociception, and so, these agents are targets for the design of a novel class of analgesics. Although synthetic agonists at the capsaicin receptor have been described previously, competitive antagonists at this receptor would be interesting and novel pharmacological agents. Structure-activity relationships for capsaicin agonists have previously been rationalized, by ourselves and others, by dividing the capsaicin molecule into three regions-the A (aromatic ring)-, B (amide bond)-, and C (hydrophobic side chain)-regions. In this study, the effects on biological activity of conformational constraint of the A-region with respect to the B-region are discussed. Conformational constraint was achieved by the introduction of saturated ring systems of different sizes. The resulting compounds provided agonists of comparable potency to unconstrained analogues as well as a moderately potent antagonist, capsazepine. This compound is the first competitive antagonist of capsaicin and resiniferatoxin to be described and is active in various systems, in vitro and in vivo. It has recently attracted considerable interest as a tool for dissecting the mechanisms by which capsaicin analogues evoke their effects. NMR spectroscopy and X-ray crystallography experiments, as well as molecular modeling techniques, were used to study the conformational behavior of a representative constrained agonist and antagonist. The conformation of the saturated ring contraint in the two cases was found to differ markedly, dramatically affecting the relative disposition of the A-ring and B-region pharmacophores. In agonist structures, the A- and B-regions were virtually coplanar in contrast to those in the antagonist, in which they were approximately orthogonal. A rationale for agonist and antagonist activity at the capsaicin receptor is proposed, based on the consideration of these conformational differences.